Literature DB >> 12457603

Sedation, anaesthesia and monitoring for bronchoscopy.

Siân I Jaggar1, Elizabeth Haxby.   

Abstract

Management of the airway for paediatric bronchoscopy requires joint planning and constant communication between the bronchoscopist and the anaesthetist. At all times maintenance of an effective airway must be the first priority. All sedative drugs compromise the patency of the airway to some extent in addition to effective ventilation by the patient. Thus, a specific individual must be dedicated to ensure adequacy of airway and ventilation throughout the procedure. Since sedation and anaesthesia are merely two points on a continuum of reduced central nervous system activation, an anaesthetist most appropriately performs this role. There is a range of drugs that may be utilised to induce sedation and a variety of airway adjuncts, which will be described. Any individual using them should be familiar with their advantages and disadvantages and be capable of managing any predictable or unusual complications.

Entities:  

Mesh:

Year:  2002        PMID: 12457603

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  3 in total

1.  Flexible fiberoptic bronchoscopy in Greek children.

Authors:  F Kirvassilis; D Gidaris; M Ventouri; A Zampouri; M Mylona; A Keramidiotis; Th Kontakiotis; I Tsanakas
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

2.  Flexible bronchoscopy contribution in the approach of diagnosis and treatment of children's respiratory diseases: the experience of a unique pediatric unit in Tunisia.

Authors:  Samia Hamouda; Amal Oueslati; Imen Belhadj; Fatma Khalsi; Faten Tinsa; Khadija Boussetta
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

3.  Application of sedation-agitation scale in conscious sedation before bronchoscopy in children.

Authors:  Lin Zhong; Kun Shen; Songhui Zhai; Ting Chen; Qingfen Tao; Lina Chen; Yuhong Tao; Li Qiu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.